EP 1432732 A2 20040630 - PHARMACEUTICAL COMPOSITION FOR DIAGNOSIS, PREVENTION OR TREATMENT OF A TUMOROUS STATE, COMPRISING A MODULATOR OF THE ACTIN POLYMERISATION STATE
Title (en)
PHARMACEUTICAL COMPOSITION FOR DIAGNOSIS, PREVENTION OR TREATMENT OF A TUMOROUS STATE, COMPRISING A MODULATOR OF THE ACTIN POLYMERISATION STATE
Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNG DIE EIN MODULATOR DES POLYMERISATIONS-ZUSTANDES VON AKTIN ENTHALTET
Title (fr)
COMPOSITION PHARMACEUTIQUE COMPRENANT UN AGENT MODULATEUR DE L'ETAT DE POLYMERISATION DE L'ACTINE
Publication
Application
Priority
- FR 0202106 W 20020618
- FR 0107976 A 20010618
Abstract (en)
[origin: FR2825928A1] Composition (A) for treatment, prevention and diagnosis of a tumor comprising an agent (I) that can stabilize the actin network of the cytoskeleton, is new. Independent claims are also included for the following: (1) non-viral vector of intracellular transport (B) associated with (I); (2) vector of intracellular transport (B') comprising a recombinant viral expression vector that includes cDNA representing the zyxin gene, or its functional fragment; (3) cell genetically modified to over- or under-express the zyxin gene; (4) transgenic mammal containing at least one cell modified for underexpression of the zyxin gene; (5) identifying (I); (6) diagnosis of tumors by quantifying expression of zyxin in patient cells; (7) phenotypic analysis of tumors by quantifying zyxin at different times and comparing expression levels to produce a differential phenotypic profile; and (8) screening compounds for antitumor activity based on measuring the stabilization of the polymerization of the actin framework in tumor cells.
IPC 1-7
C07K 14/47; A61K 38/17; C12N 5/10; A61K 31/713; A61K 38/12; A61K 48/00; G01N 33/50; G01N 33/68; A61P 35/00
IPC 8 full level
A01K 67/027 (2006.01); A61K 35/12 (2015.01); A61K 35/28 (2015.01); A61K 35/76 (2015.01); A61K 35/761 (2015.01); A61K 38/00 (2006.01); A61K 45/00 (2006.01); A61K 48/00 (2006.01); A61P 7/00 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C12N 5/10 (2006.01); C12N 15/09 (2006.01); C12N 15/113 (2010.01); C12Q 1/02 (2006.01); C12Q 1/68 (2006.01); G01N 33/15 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01)
CPC (source: EP US)
A61P 7/00 (2018.01 - EP); A61P 35/00 (2018.01 - EP); C07K 14/47 (2013.01 - EP US); C12N 15/113 (2013.01 - EP US)
Citation (examination)
WO 0033888 A2 20000615 - COULTER PHARM INC [US], et al
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
FR 2825928 A1 20021220; FR 2825928 B1 20040402; AU 2002317259 A1 20030102; CA 2450845 A1 20021227; EP 1432732 A2 20040630; JP 2005504521 A 20050217; JP 4271026 B2 20090603; US 2004191230 A1 20040930; US 2009286720 A1 20091119; WO 02102846 A2 20021227; WO 02102846 A3 20040422; WO 02102846 B1 20040603
DOCDB simple family (application)
FR 0107976 A 20010618; AU 2002317259 A 20020618; CA 2450845 A 20020618; EP 02745538 A 20020618; FR 0202106 W 20020618; JP 2003506318 A 20020618; US 42683309 A 20090420; US 74026603 A 20031218